Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA.
Departments of Anesthesia and Critical Care, McMaster University, Hamilton, ON, Canada; Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
Br J Anaesth. 2022 May;128(5):772-784. doi: 10.1016/j.bja.2021.11.040. Epub 2022 Jan 29.
There is controversy regarding optimal use of benzodiazepines during cardiac surgery, and it is unknown whether and to what extent there is variation in practice. We sought to describe benzodiazepine use and sources of variation during cardiac surgeries across patients, clinicians, and institutions.
We conducted an analysis of adult cardiac surgeries across a multicentre consortium of USA academic and private hospitals from 2014 to 2019. The primary outcome was administration of a benzodiazepine from 2 h before anaesthesia start until anaesthesia end. Institutional-, clinician-, and patient-level variables were analysed via multilevel mixed-effects models.
Of 65 508 patients cared for by 825 anaesthesiology attending clinicians (consultants) at 33 institutions, 58 004 patients (88.5%) received benzodiazepines with a median midazolam-equivalent dose of 4.0 mg (inter-quartile range [IQR], 2.0-6.0 mg). Variation in benzodiazepine dosage administration was 54.7% attributable to institution, 14.7% to primary attending anaesthesiology clinician, and 30.5% to patient factors. The adjusted median odds ratio for two similar patients receiving a benzodiazepine was 2.68 between two randomly selected clinicians and 4.19 between two randomly selected institutions. Factors strongly associated (adjusted odds ratio, <0.75, or >1.25) with significantly decreased likelihoods of benzodiazepine administration included older age (>80 vs ≤50 yr; adjusted odds ratio=0.04; 95% CI, 0.04-0.05), university affiliation (0.08, 0.02-0.35), recent year of surgery (0.42, 0.37-0.49), and low clinician case volume (0.44, 0.25-0.75). Factors strongly associated with significantly increased likelihoods of benzodiazepine administration included cardiopulmonary bypass (2.26, 1.99-2.55), and drug use history (1.29, 1.02-1.65).
Two-thirds of the variation in benzodiazepine administration during cardiac surgery are associated with institutions and attending anaesthesiology clinicians (consultants). These data, showing wide variations in administration, suggest that rigorous research is needed to guide evidence-based and patient-centred benzodiazepine administration.
在心脏手术期间,苯二氮䓬类药物的最佳使用存在争议,并且尚不清楚实践中是否存在差异以及差异的程度如何。我们旨在描述心脏手术期间患者、临床医生和医疗机构中苯二氮䓬类药物的使用情况和差异来源。
我们对来自美国学术和私立医院的多中心联盟 2014 年至 2019 年期间的成年心脏手术进行了分析。主要结局是在麻醉开始前 2 小时至麻醉结束期间给予苯二氮䓬类药物。通过多水平混合效应模型分析机构、临床医生和患者水平的变量。
在由 33 家机构的 825 名麻醉学主治医生(顾问)护理的 65508 名患者中,58004 名患者(88.5%)接受了苯二氮䓬类药物治疗,咪达唑仑等效剂量中位数为 4.0mg(四分位距[IQR],2.0-6.0mg)。苯二氮䓬类药物剂量给药的变异性有 54.7%归因于机构,14.7%归因于主要主治麻醉学临床医生,30.5%归因于患者因素。接受苯二氮䓬类药物治疗的两名相似患者的调整后中位数优势比为两名随机选择的临床医生之间为 2.68,两名随机选择的机构之间为 4.19。与显著降低苯二氮䓬类药物给药可能性相关的因素(调整后的优势比,<0.75 或>1.25)包括年龄较大(>80 岁与≤50 岁;调整后的优势比=0.04;95%CI,0.04-0.05)、大学附属关系(0.08,0.02-0.35)、手术时间较近(0.42,0.37-0.49)和临床医生低手术量(0.44,0.25-0.75)。与显著增加苯二氮䓬类药物给药可能性相关的因素包括体外循环(2.26,1.99-2.55)和药物使用史(1.29,1.02-1.65)。
心脏手术期间苯二氮䓬类药物给药的三分之二差异与机构和主治麻醉学临床医生(顾问)有关。这些数据表明,给药存在广泛差异,这表明需要进行严格的研究,以指导基于证据和以患者为中心的苯二氮䓬类药物给药。